Pharma and Biotech Daily: Stay Informed with the Latest Industry Updates

Pharma and BioTech Daily

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل two أعوام

المحتوى المقدم من Pharma and BioTech News and BioTech News. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Pharma and BioTech News and BioTech News أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

Exile

1
Episode 10: From Refugee to Radical 44:09

منذ 2 years44:09

التشغيل لاحقا

قوائم

إعجاب

احب

44:09

When a young Eva Kollisch arrives as a refugee in New York in 1940, she finds a community among socialists who share her values and idealism. She soon discovers ‘the cause’ isn’t as idyllic as it seems. Little does she know this is the beginning of a lifelong commitment to activism and her determination to create radical change in ways that include belonging, love and one's full self. In addition to Eva Kollisch’s memoirs Girl in Movement (2000) and The Ground Under My Feet (2014), LBI’s collections include an oral history interview with Eva conducted in 2014 and the papers of Eva’s mother, poet Margarete Kolllisch, which document Eva’s childhood experience on the Kindertransport. Learn more at www.lbi.org/kollisch . Exile is a production of the Leo Baeck Institute , New York | Berlin and Antica Productions . It’s narrated by Mandy Patinkin. Executive Producers include Katrina Onstad, Stuart Coxe, and Bernie Blum. Senior Producer is Debbie Pacheco. Associate Producers are Hailey Choi and Emily Morantz. Research and translation by Isabella Kempf. Sound design and audio mix by Philip Wilson, with help from Cameron McIver. Theme music by Oliver Wickham. Voice acting by Natalia Bushnik. Special thanks to the Kollisch family for the use of Eva’s two memoirs, “Girl in Movement” and “The Ground Under My Feet”, the Sophia Smith Collection at Smith College and their “Voices of Feminism Oral History Project”, and Soundtrack New York.…

منذ عام واحد 1:09

MP3•منزل الحلقة

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Roche is planning to be cautious with high-priced deals in 2025, prioritizing putting science at the center of its business development decisions. Sanofi's recent earnings were driven by Dupixent and a new RSV vaccine, with a strong focus on R&D and potential M&A deals. Inhibikase has decided to scrap a Parkinson's drug after disappointing mid-stage data, adding to recent setbacks in the field. RFK Jr. faced a divided Senate during his confirmation hearing for HHS secretary, downplaying concerns about his previous anti-vax statements. Vertex is awaiting the FDA verdict on a non-opioid pain drug, while Ironwood has made the decision to cut half of its staff due to disappointing 2025 guidance. Zentalis is planning to lay off 40% of its staff in order to extend its cash runway. The life sciences scene in the Chicago area continues to show growth.In the latest news, The Weekly covers RFK Jr.'s Senate hearing, Sage's rejection of Biogen, and developments in the obesity space. Thank you for tuning in to Pharma and Biotech Daily.

65 حلقات

#News #Tech News #Pharma and BioTech News #BioTech News #Pharma #Biotech #Genomics #Artificial Intelligence

Pharma and Biotech Daily: Stay Informed with the Latest Industry Updates

Pharma and BioTech Daily

published منذ عام واحد

MP3•منزل الحلقة

65 حلقات

#News #Tech News #Pharma and BioTech News #BioTech News #Pharma #Biotech #Genomics #Artificial Intelligence

كل الحلقات

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Novo Nordisk's Wegovy Program and Challenges Facing Rare Disease Biotechs 1:27

منذ 15 hours1:27

1:27

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk has launched a direct-to-consumer program for their drug Wegovy, offering it at a reduced price of $499 per month for uninsured or underinsured patients, less than half of the drug's list price. Meanwhile, rare disease biotechs are facing challenges as Congress has failed to renew the rare pediatric disease priority review program, creating uncertainty and concerns within the biopharma industry. Congress failed to renew the rare pediatric disease priority review program at the end of 2024, leaving rare disease biotechs in a difficult position. Companies spent $513 million on priority review vouchers in 2024. Delphia, a biotech company, launched a new precision medicine approach called Activation Lethality in May 2024. The top 10 best-selling drugs of 2024 included Merck's Keytruda and Abbvie's Humira. Pfizer is prepared to reshore manufacturing if tariff threats are realized. Other news includes BridgeBio Oncology's plan to go public, Abbvie's deal with Gubra, and GSK CEO Emma Walmsley's pay increase. Industry leaders will be discussing the future of orphan drug development and rare disease care at the upcoming World Orphan Drug Congress in 2025. Annalee Armstrong, senior editor for Biospace, invites readers to suggest topics for future coverage and provide feedback to improve their Biospace experience.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Reshoring, Setbacks, and Successes 0:39

منذ 1 day0:39

0:39

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Pfizer and Eli Lilly are considering reshoring manufacturing in the U.S. in response to President Trump's tariff threats. Biohaven faces setbacks in clinical trials, while Roche gains FDA approval for a stroke drug expansion. Startup Delphia aims to use a precision medicine approach to target cancer cells. Industry leaders will discuss orphan drug development at the World Orphan Drug Congress 2025. Other news includes Beigene's label expansion, AstraZeneca and Daiichi Sankyo's success with Enhertu in stomach cancer, and Atara's restructuring.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Your Essential Update on Industry Trends and Opportunities 1:28

منذ 3 أيام1:28

1:28

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. AbbVie has recently entered the obesity market through a deal with Gubra for Amylin, worth up to $2.2 billion. This move positions AbbVie among industry leaders like Novo Nordisk and Eli Lilly. The focus on redefining obesity as a chronic disease is gaining momentum, with recent FDA documents and The Lancet Diabetes & Endocrinology commission highlighting the importance of maintenance treatment. In immuno-oncology, experts are searching for the next breakthrough beyond Keytruda and Yervoy. Novel targets, combinations, and pre-emptive immunization are being explored as potential areas of growth. The upcoming World Orphan Drug Congress in 2025 will gather industry leaders to discuss the future of orphan drug development and rare disease care. Positive developments have been reported for Biogen and Eisai's Leqvio in Europe, AstraZeneca and Amgen's Phase III win for Tezspire, and advancements in non-opioid painkillers by Lexicon. The text also discusses the maturation of immuno-oncology, the potential of mRNA technology in rare diseases, recent FDA approvals for rare disease treatments, the evolving mindset towards treating obesity as a chronic disease, and updates on FDA-related news. Lastly, job opportunities in the biotech industry are available at AbbVie, Moderna, Arvinas Inc., and Sonothera. Share your input on topics to cover in the biopharma industry.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Breaking News in the World of Healthcare Innovation 1:01

منذ 4 أيام1:01

1:01

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly has entered a $1.6 billion deal in the molecular glue space, following the steps of other big pharma players like Novo Nordisk, Pfizer, and Novartis. On the other hand, the FDA, NIH, and CDC are experiencing chaos with canceled meetings and postponed discussions since Donald Trump's return as U.S. president, without a clear reason. In other news, Cassava's stock is on the rise after licensing seizure rights for simufilam, while BridgeBio Oncology is going public through a SPAC deal. Meanwhile, Vertex has decided to sever a partnership for liver gene therapies. Trilink is offering mRNA designs for reliable performance, and Eisai is planning to cut 7% of its US workforce.The role of mRNA in bridging the innovation gap in rare diseases is being discussed, highlighting the importance of industry and AI in fighting misinformation and empowering patients.Thank you for tuning in to Pharma and Biotech daily.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: The Weekly Roundup in the World of Pharma and Biotech 0:44

منذ 7 أيام0:44

0:44

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. The FDA's vaccine planning meeting was canceled due to disruptions caused by Robert F. Kennedy Jr. GSK's CEO Emma Walmsley received a pay increase to align with industry standards. Lilly invested $27 billion in US manufacturing after Trump's tariff threats. Regeneron scaled back approval goals for a lymphoma bispecific drug. Kallyope released disappointing data for an oral obesity candidate. Trilink offers mRNA designs for reliable performance. Congress reintroduced the EPIC Act to remove IRA's 'pill penalty'. Layoffs were announced at Lava and Ryvu, with new job opportunities in the life sciences industry available.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Navigating the Ever-Evolving Landscape 1:32

منذ 8 أيام1:32

1:32

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The Epic Act has been reintroduced in Congress to remove the IRA's 'pill penalty', with hopes for positive changes. However, budgetary constraints may make it challenging for the current administration to make significant amendments to the IRA. As money continues to flow into weight loss drugs, physicians are prioritizing efficacy and access. Emalex is moving towards FDA approval after a successful Phase III trial for Tourette Syndrome. AstraZeneca also received positive Phase III results for an oral breast cancer drug. SpringWorks Therapeutics successfully turned a Pfizer 'ghost drug' into a victory by keeping a rare disease program alive with the help of advocacy groups. This success story has led experts to believe that this method could be applied to other rare diseases as well. The company serves as a case study for how to mine biopharma's IP storeroom for rare disease drugs.Meanwhile, weight loss doctors are seeking better GLP-1 medications, but are facing challenges with high prices and supply issues. Trump is threatening big pharma with tariffs unless they reshore manufacturing. Bluebird Bio is facing financial challenges and may go private in a deal valued at $30 million. Compounders are suing the FDA over declaring a shortage of certain drugs, while the FTC is tightening merger rules despite the Trump administration's pro-industry stance.These updates show the ever-evolving landscape of the pharmaceutical and biotech industries. Stay tuned for more important news and developments in the field.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Stay Informed on Industry News and Developments 1:14

منذ 9 أيام1:14

1:14

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. J&J is currently involved in a legal battle with Samsung Bioepis, alleging unlawful sublicensing of a Stelara biosimilar. Meanwhile, Takeda has made a significant investment in a new BridGene partnership aimed at targeting undruggable targets. In other news, Regeneron has made strides in developing a gene therapy that can restore hearing in patients with rare genetic deafness. However, Deerfield Management claims that Alcon is hindering Aurion Biotech's IPO progress. Additionally, Trilink is offering mRNA designs that ensure reliable performance across various applications. There have also been reports of compounders suing the FDA, Reperio Therapeutics downsizing their staff, and discussions on how to support small molecule innovations in the industry. And if you missed it, recent developments include Trump threatening big pharma with tariffs, the FDA rehiring scientists, and advancements in pain treatment, RNA editing, and gene therapies being highlighted. Opportunities in neuroscience sales, regulatory affairs, and marketing are currently available for those interested. Thank you for tuning in to Pharma and Biotech Daily for the latest updates in the industry.…

Pharma and BioTech Daily

1
Breaking News in Pharma and Biotech: From Trump's Tariffs to RNA Editing 1:44

منذ 10 أيام1:44

1:44

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has threatened big pharma with tariffs unless they reshore manufacturing. He also refused to promise pharma executives that he would hamstring the IRA's drug negotiation program. RNA editing is fueling hope for rare and common diseases, with experts calling for more efficiency and breakthroughs in delivery methods. The FDA is rehiring scientists after Trump's firing spree, with around 300 staff being asked to return. Vertex's Journavx is changing the pain treatment landscape, but opioids are still prevalent. Trilink offers mRNA designs for reliable performance in various applications. In other news, a small Harvard start-up is fighting antimicrobial resistance, and OpinionAI is focusing on small molecules in the I&I space. Bluebird is going private, Mirum receives FDA approval for a rare disease, and PhRMA is meeting with Trump on various policies.Vertex's Journavx is changing the landscape of pain treatment, but opioids are still widely used. Non-opioid pain therapies, including Journavx, have been approved by the FDA, but their uptake remains uncertain. Meanwhile, RNA editing is showing promise in clinical trials for treating rare and common diseases, and artificial intelligence is making small molecules more attractive in the inflammatory and immunology disease space. The FDA is facing low morale after job cuts under Trump's administration, raising concerns about delays in new medicine approvals. Additional news includes Sanofi challenging Novo with an FDA approval for a biosimilar, FDA rare cancer approvals, and Lead passing on an option for Arcus' cancer drug.Thank you for tuning in to Pharma and Biotech Daily.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: FDA Approves New Treatments and Collaborations in the Industry 3:09

منذ 11 يومًا3:09

3:09

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Title: Pfizer and BioNTech seek FDA approval for COVID-19 vaccine boosterPfizer and BioNTech have announced that they are seeking authorization from the FDA for a booster dose of their COVID-19 vaccine. The companies have presented data showing that a third dose of the vaccine can significantly increase protection against the Delta variant.##Title: Moderna to supply 100 million more doses of COVID-19 vaccine to the USModerna has reached an agreement with the US government to supply an additional 100 million doses of its COVID-19 vaccine. The company will deliver the doses by the end of the year, helping to boost vaccination efforts across the country.##Title: AstraZeneca's COVID-19 antibody treatment shows promising results in clinical trialsAstraZeneca has announced that its COVID-19 antibody treatment has shown promising results in clinical trials. The treatment, which is designed to prevent severe disease and hospitalization, could provide an important new tool in the fight against the virus.##Title: Novartis receives FDA approval for new treatment for advanced breast cancerNovartis has received FDA approval for a new treatment for advanced breast cancer. The drug, which targets a specific genetic mutation, has been shown to significantly improve progression-free survival in patients with the disease.##Title: Roche announces positive results from phase 3 trial of Alzheimer's drugRoche has announced positive results from a phase 3 trial of its Alzheimer's drug. The drug, which is designed to target the underlying cause of the disease, showed significant improvement in cognitive function and daily living activities in patients with early-stage Alzheimer's.##Title: Johnson & Johnson to invest $6.5 billion in expanding vaccine production capacityJohnson & Johnson has announced plans to invest $6.5 billion in expanding its vaccine production capacity. The company aims to increase production of its COVID-19 vaccine as well as other vaccines in its portfolio, helping to address global supply shortages.##Title: Merck receives FDA approval for new treatment for certain types of lung cancerMerck has received FDA approval for a new treatment for certain types of lung cancer. The drug, which targets a specific genetic mutation, has been shown to improve overall survival in patients with advanced disease.##Title: Gilead Sciences announces collaboration with Novartis on HIV researchGilead Sciences has announced a collaboration with Novartis on HIV research. The companies will work together to develop new treatments for HIV, with a focus on addressing drug resistance and improving outcomes for patients with the virus.## Title: Eli Lilly receives FDA approval for new treatment for migraineEli Lilly has received FDA approval for a new treatment for migraine. The drug, which is administered through an injection, has been shown to provide rapid relief from migraine symptoms and reduce the frequency of attacks in patients with the condition.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Your Daily Dose of What Matters in the Pharma and Biotech World 4:05

منذ 14 يومًا4:05

4:05

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##COVID-19 vaccine distribution challenges##As the world races to distribute COVID-19 vaccines, challenges arise in ensuring equitable distribution. Limited supplies, logistical issues, and vaccine hesitancy all contribute to the complexity of the distribution process. Governments and organizations must work together to address these challenges and ensure that vaccines reach all those in need.##FDA approves new cancer treatment##The FDA has recently approved a new cancer treatment that shows promising results in clinical trials. This treatment offers hope to patients with certain types of cancer who have not responded well to traditional therapies. The approval highlights the importance of ongoing research and innovation in the field of oncology.##Pharmaceutical company announces breakthrough in Alzheimer's research##A pharmaceutical company has announced a major breakthrough in Alzheimer's research, potentially paving the way for new treatments for this devastating disease. The discovery represents a significant advancement in our understanding of Alzheimer's and offers hope to millions of patients and their families.##Biotech firm receives funding for rare disease research##A biotech firm has secured funding to support research into a rare disease that affects a small but vulnerable population. This funding will enable the firm to continue its work in developing new treatments and ultimately improving the lives of those affected by this rare disease.##Regulatory approval granted for innovative gene therapy##Regulatory approval has been granted for an innovative gene therapy that has shown promising results in clinical trials. This therapy represents a new frontier in the treatment of genetic disorders and offers hope to patients who previously had limited treatment options. The approval highlights the potential of gene therapy as a transformative technology in healthcare.##Pharma company collaborates with academia on drug discovery##A pharmaceutical company has announced a collaboration with academia to accelerate drug discovery efforts. By combining industry expertise with academic research capabilities, the collaboration aims to identify and develop novel therapies for a range of diseases. This partnership demonstrates the power of collaboration in driving innovation in drug discovery.##Biotech startup receives grant for antibiotic development##A biotech startup has been awarded a grant to support its work in developing new antibiotics to combat antimicrobial resistance. This funding will allow the startup to continue its research and development efforts, with the ultimate goal of bringing new antibiotics to market. The grant highlights the importance of addressing the growing threat of antimicrobial resistance through innovative research initiatives.##Pharma company acquires biotech firm to expand pipeline##A pharmaceutical company has acquired a biotech firm in a strategic move to expand its pipeline of novel therapies. This acquisition will allow the company to access new technologies and research capabilities, strengthening its position in the competitive pharmaceutical market. The acquisition underscores the importance of strategic partnerships and acquisitions in driving innovation and growth in the industry.##Biotech company announces positive results from clinical trial##A biotech company has announced positive results from a clinical trial of its experimental therapy for a rare genetic disorder. The therapy showed promising efficacy and safety outcomes, raising hopes for patients with this debilitating condition. The results highlight the potential of precision medicine approaches in treating rare genetic disorders.##Pharma industry invests in digital health technologies##The pharmaceutical industry is increasingly investing in…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: The Latest in Industry News and Trends 2:03

منذ 15 يومًا2:03

2:03

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. A lawsuit against Merck related to the HPV vaccine Gardasil, led by Robert F. Kennedy Jr., has been suspended after confirmation. Biopharma bankruptcies are at a peak, with 14 companies filing for chapter 11 protection in 2023 and numbers remaining high in 2024. Gilead has passed on an option for a cancer drug from Arcus, and Merck has partnered with Epitopea to identify unknown tumor antigens. The American Biomanufacturing Summit is set to take place in April 2025 in San Francisco, bringing together industry leaders for exclusive sessions and networking opportunities. The pharmaceutical industry is facing challenges such as patent cliffs and regulatory changes, with companies like Exelixis looking to next-generation cancer drugs for growth. Novo is seeking $830 million in a fraud case against a Singaporean biotech company over a kidney drug. Additionally, there are insights on site survival for clinical research sites and how biotechs can avoid state and local tax surprises. Trump's administration is reportedly seeking to dismantle parts of the FDA workforce, leading to concerns about job security within the agency.Biopharma bankruptcies remained high in 2024, with 14 companies filing for chapter 11 protection, the most in over a decade. Cour Pharmaceuticals solidified its mission last year with a series a raise. Some biotechs are facing unexpected tax consequences when dealing with big pharma. Several top pharma companies are facing massive patent cliffs, including Merck's Keytruda. Novo seeks $830 million in a fraud case against a Singaporean biotech, while Exelixis looks to next-gen cancer drugs. Biogen and Stoke strike a co-development deal for Dravet syndrome. The FDA faces uncertainty as the Trump team seeks to dismantle the workforce. Aardvark Therapeutics raises $94 million for obesity treatments. Abbott, Life Edit Therapeutics, and Regeneron Pharmaceuticals are hiring for various positions.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Lawsuits, Partnerships, and FDA Challenges 1:04

منذ 16 يومًا1:04

1:04

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novo Nordisk has filed a lawsuit against Singaporean biotech company KBP Biosciences, alleging fraud in relation to a hypertension and kidney disease drug deal. Novo seeks $830 million in damages, claiming they were misled by the biotech's founder. In other news, Biogen and Stoke have teamed up to develop a treatment for Dravet syndrome, with potential payments of up to $385 million to Stoke. Additionally, Arcus challenges Merck in kidney cancer treatment, Cour Pharmaceuticals enters the myasthenia gravis arena after 10 years of work. On the financial side, AlgoTx faced setbacks in a non-opioid pain trial, while Moderna reported higher-than-expected losses. On a different note, RFK Jr. signals support for the psychedelics space. Lastly, the FDA faces challenges as the Trump administration seeks to dismantle the workforce, leading to concerns about job security within the agency. Thank you for tuning in to Pharma and Biotech Daily.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Navigating the Latest Industry Shifts and Innovations 1:05

منذ 17 يومًا1:05

1:05

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. The Trump administration's staffing purge has now impacted the FDA, leading to layoffs of employees after Robert F. Kennedy Jr.'s confirmation as HHS secretary. Despite these changes, vaccine approvals are still progressing as usual.Biopharma companies are making significant investments in immunology and inflammation research, focusing on finding new targets and pathways for diseases like inflammatory bowel disease and atopic dermatitis. The FDA has recently approved multiple vaccines back-to-back, even as Kennedy, known for his vaccine skepticism, assumes a leadership role at the HHS.In other news, the American Biomanufacturing Summit is scheduled for April 2025, offering industry leaders a platform for networking and informative sessions. Updates in the psychedelics space, biosimilar approvals, and recent layoffs at Kojin impacting 25 employees are also making headlines.Opportunities in the biopharma industry continue to grow, with job openings highlighted in the newsletter.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Moderna's Losses, RFK Jr.'s Appointment, and More Updates 0:52

منذ 18 يومًا0:52

0:52

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna reported higher-than-expected losses in its fourth-quarter earnings report and is anticipating layoffs. The company's revenue was down substantially from the previous year. Meanwhile, controversial figure RFK Jr. was confirmed as the Health and Human Services Secretary, despite his history of anti-vaccine rhetoric. In other news, BMS' phase III Opdivo and Yervoy combination therapy failed in adjuvant melanoma, potentially limiting market opportunities. Amgen and Ideaya have ended their collaboration on a cancer combo therapy, with Amgen continuing to advance one component in a mid-stage trial for lung cancer. Pliant has brought in outside experts to review a study pause in idiopathic pulmonary fibrosis research. Stay tuned for more updates on various biopharma companies and their developments.…

Pharma and BioTech Daily

1
Pharma and Biotech Daily: Novo's Semaglutide, FDA Job Cuts, Sanofi's Impairment, and More! 0:58

منذ 21 يومًا0:58

0:58

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo's semaglutide shows promise in curbing alcohol use disorder, according to data published in JAMA Psychiatry. This supports the use of GLP-1 receptor agonists for addictive disorders. Meanwhile, the Trump administration is considering job cuts at the FDA. This could potentially lead to uncertainty and delays in regulatory reviews.In other news, Sanofi is facing a $250 million impairment after scrapping a J&J-partnered E. coli vaccine. Roche's Evrysdi has become the first pill cleared for spinal muscular atrophy. Pfizer has expanded the label for Adcetris to include non-Hodgkin lymphomas.Additionally, Newleos Therapeutics has raised $93.5 million to advance neuropsychiatric drugs from Roche's pipeline. All this information was shared by BioSpace, a platform that provides updates on the biotech and pharmaceutical industry.…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

الاستماع إلى +500 موضوع

مشابه لـPharma and BioTech Daily

Marvel Legends Series Daredevil: Born Again Daredevil Collectible 6-Inch Action Figure

TERRO T300B Liquid Ant Killer, 12 Bait Stations

everydrop by Whirlpool Ice and Water Refrigerator Filter 1, EDR1RXD1, Single-Pack , Purple

المدونة الصوتية تستحق الاستماع

Pharma and BioTech Daily « » Pharma and Biotech Daily: Stay Informed with the Latest Industry Updates

Pharma and Biotech Daily: Stay Informed with the Latest Industry Updates

المدونة الصوتية تستحق الاستماع

مرحبًا بك في مشغل أف ام!

Ailun 3 Pack Screen Protector for iPhone 16 Pro Max [6.9 inch] + 3 Pack Camera Lens Protector with Installation Frame,Sensor Protection,Dynamic Island Compatible,Case Friendly Tempered Glass Film

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Minecraft

Bounty Paper Towels Quick Size, White, 16 Family Rolls = 40 Regular Rolls (Packaging May Vary)

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

مشابه لـPharma and BioTech Daily

دليل مرجعي سريع

Pharma and BioTech Daily « »
Pharma and Biotech Daily: Stay Informed with the Latest Industry Updates